VetriBute PasteThis page contains information on VetriBute Paste for veterinary use.
The information provided typically includes the following:
- VetriBute Paste Indications
- Warnings and cautions for VetriBute Paste
- Direction and dosage information for VetriBute Paste
VetriBute PasteThis treatment applies to the following species:
ANADA 200-266, Approved by FDA
For Veterinary Use Only
Phenylbutazone Paste is a synthetic, non-hormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound’s anti-inflammatory properties.
Chemically, Phenylbutazone Paste is 4-butyl-1, 2-diphenyl-3, 5-pyrazolidinedione. It is a pyrazolone derivative, entirely unrelated to the steroid hormones.
VetriBute Paste Indications
For the relief of inflammatory conditions associated with the musculoskeletal systems in horses.
Use with caution in patients who have a history of drug allergy.
WARNING: Not for use in horses intended for food.
PrecautionsStop medication at the first sign of gastrointestinal upset, jaundice, or blood dyscrasia. Authenticated cases of agranulocytosis associated with the drug have occurred in man; fatal reactions, although rare, have been reported in dogs after long-term therapy. To guard against this possibility, conduct routine blood counts at weekly intervals during the early phase of therapy and at intervals of two weeks thereafter. Any significant fall in the total white blood cell count, relative decrease in granulocytes, or black or tarry stools, should be regarded as a signal for immediate cessation of therapy and institution of the appropriate counter-measures. In the treatment of inflammatory conditions associated with infections, specific anti-infective therapy is required.
ADMINISTRATION AND DOSAGE: Orally - 1 to 2 g of phenylbutazone per 500 lb. of body weight daily. Do not exceed 4 g daily.
Guidelines to Successful Therapy: Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain lowest dose capable of producing desired clinical response. Response to Phenylbutazone Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical effect is evident after five days, re-evaluate diagnosis and therapeutic approach. When administering Phenylbutazone Paste, the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose. Many chronic conditions will respond to Phenylbutazone Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.
StorageStore at 15°-30°C (59°-86°F).
How SuppliedSyringes containing 20 g of Phenylbutazone.
KEEP OUT OF REACH OF CHILDREN
VetriBute Paste Caution
Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Each syringe contains 20 g phenylbutazone. Each 3 mL marking on the plunger contains Phenylbutazone: 1 g.
Manufactured by: Med-Pharmex, Inc., Pomona, CA 91767-1861
Distributed by: MWI, Boise, ID 83705
MADE IN USA
NAC No.: 13151680
Distributed by MWI Animal Health
3041 W. PASADENA DR., BOISE, ID, 83705
|Every effort has been made to ensure the accuracy of the VetriBute Paste information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2016 North American Compendiums. Updated: 2016-10-31